REGENXBIO Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $9.2 million (-69.2% year over year) and diluted EPS of -$0.62. It usually reports 36–64 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 4, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Mar 5, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–64 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
9
-69.2%
|
-41
+34.2%
|
-0.62
+48.3%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
108
+405.7%
|
23
+132.0%
|
0.43
+131.2%
|
|
May 14, 2026
44 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
6
-92.8%
|
-90
-1580.4%
|
-1.72
-1533.3%
|
|
Mar 5, 2026
64 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
30
+43.0%
|
-67
-31.2%
|
-1.30
-28.9%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
30
+22.9%
|
-62
-3.9%
|
-1.20
-2.6%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
21
-4.2%
|
-71
-33.7%
|
-1.38
-31.4%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
89
+469.8%
|
6
+109.6%
|
0.12
+108.7%
|
|
Mar 13, 2025
72 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
21
-4.5%
|
-51
+18.6%
|
-1.01
+29.6%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RGNX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Rockville, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1590877
- Former names
- ReGenX Biosciences, LLC (until Nov 7, 2013)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.